Antoxerene, Inc., a portfolio company of Ichor Therapeutics, Inc., is a pharmaceutical company that uses proprietary next generation screening technology to identify small molecule drugs for pathways of aging.
At the cellular level, communication within the body occurs through protein interactions. These communication pathways can be enhanced or inhibited using small molecule compounds, which serve as the active ingredient of many disease-treating drugs.
A major technical challenge in screening for new small molecule drug leads is scalable manufacturing of the target proteins. Antoxerene uses a proprietary technology to generate proteins that cannot be manufactured at scale using traditional approaches, enabling screening on many previously non-druggable pathways. The Antoxerene team has successfully found small molecule hits on several difficult or new pathways.